The uric acid-lowering effect and safety of a fermented barley extract P (FBEP) prepared from barleyshochu distillery by-products were investigated in a randomized, placebo-controlled, parallel-group, doubleblinded study. A total of 111 subjects with serum uric acid levels of 6.0-7.9 mg/dl were provided with either a drink containing 2 g/d of FBEP (test group) or a placebo drink. After 12 weeks, the serum uric acid levels changed by À0:21 AE 0:56 mg/dl in the test group, showing a significant decrease in comparison to those of the placebo group (þ0:02 AE 0:54 mg/dl). Additionally, the uric acid clearance in the test group showed a tendency to increase after 12 weeks more than in the placebo group (p ¼ 0:054). No abnormalities in the physical and clinical tests were observed, and no adverse diagnostic findings were attributed to the intake of the test meal. These results demonstrated the benefits and safety of the FBEP treatment to subjects with slightly high serum uric acid or mild hyperuricemia.
The number of cases in Japan of gout and its cause, hyperuricemia, have been increasing yearly as a result of the adoption of westernized and Americanized diets. Even though there have been few epidemiological studies, the incidences of gout and hyperuricemia have also been increasing worldwide with changes in environmental factors. 1, 2) The Japanese Society of Gout and Nucleic Acid Metabolism defines hyperuricemia as a condition with over 7.0 mg/dl of serum uric acid, irrespective of the gender and age. Hyperuricemia has been attracting attention not only as the underlying cause of gout, but also as an independent predictive factor in cardiac and cerebrovascular disorders. 3, 4) Hyperuricemia is classified into 3 types: the increased production type, in which uric acid is excessively produced; the decreased excretion type, in which the capability for uric acid excretion is reduced due to decreased renal function; and the mixed type, which is a combination of both the above types. Eighty-five percent of all the cases of gout and hyperuricemia in Japan involve decreased excretion of uric acid from the kidney. 5, 6) It has been reported that chitosan, as a foodstuff, decreases serum uric acid by inhibiting the absorption of purine. 7) However, it has not been reported that a foodstuff can effectively decrease serum uric acid in humans by accelerating the uric acid excretion.
We have studied the effective application of shochu distillery by-products (SDB) and have reported the effects of a fermented barley extract (FBE) obtained from barley-SDB. The effects of FBE on preventing fatty liver induction by orotic acid, 8) preventing liver injury caused by D-galactosamine 9) and preventing alcohol-induced liver injury have been reported. 10) Additionally, in an exploratory open study, we have reported that supplementation with FBEP at a dose of 2 g/d reduced serum uric acid in subjects with slightly high serum uric acid or mild hyperuricemia.
11) The present study was aimed at making a further, detailed examination of the effectiveness and safety of FBEP. We conducted a double-blind study of Japanese men and women with slightly elevated serum uric acid levels, but who did not require treatment for this.
Materials and Methods
Subjects. The test was carried out on Japanese men and women with a serum uric acid level of 6.0-7.9 mg/dl and an age range of 20-65 years. The exclusion criteria were as follows: i) Those who had gout. ii) Those who made regular use of medicines and/or foods that might influence the serum uric acid level.
iii) Those who had severe diseases such as diabetes mellitus, liver disorders, renal disorders, or cardiovascular diseases.
iv) Those who, at the examination prior to the trial, had both over urinary protein levels and positive urinary creatinine levels, or having over 2þ urinary protein levels. v) Those who had any food allergies. vi) Those who were already enrolled in another study at the start of this study.
vii) Those who were pregnant, breast-feeding or expected to become pregnant during the study period.
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Prior to treatment, we performed two pre-test examinations, four weeks apart, and selected 111 subjects who met the eligibility criteria. The present test was executed while abiding with the ethical guidelines that are in accordance with the Helsinki Declaration and the Ethical Guidelines for Epidemiological Research, Japan (notified by Ministry of Education, Culture, Sports, Science and Technology and Ministry of Health, Labor and Welfare).
Test food. FBEP, obtained from barley (Hordeum vulgare f. distichon) SDB, was evaluated in a clinical examination. Food-grade instruments were used for preparing FBEP. Barley SDB provided by Sanwa Shurui (Oita, Japan) was prepared from pearled barley (PB; barley pearled to approximately 65% of its initial weight) as the raw material. To produce steamed barley, PB was allowed to absorb water until a 40% w/w water content was achieved, steamed for 40 min, and subsequently cooled to 40 C. The barley koji was produced by inoculating the steamed barley with white koji mold (Aspergillus kawachii) (1 kg/ton of barley) which was maintained at 38 C and 95% relative humidity (RH) for 24 h with a subsequent incubation at 32 C and 92% RH for 20 h. The seed mash was prepared with 3.6 kl water, 30-liter of a shochu yeast (Saccharomyces cerevisiae) preculture (3 Â 10 8 cfu/ml) and 3 tons of barley koji. The seed mash was fermented for 5 d at 25 C. The main mash was prepared by adding 7 tons of steamed barley and 11.4 kl of water to the seed mash. The main mash was fermented for 11 d at 25 C. After fermentation, the main mash was subjected to single-batch distillation to obtain 10 kl of unrefined barley shochu and 15 kl of barley SDB. The barley SDB was filtered through a stainless-steel mesh (1 mm). The extracted liquid was then filtered through a ceramic filter (0.2 mm porosity) to remove such solids as plant cell walls and microbial cells. A 10-liter volume of the aqueous solution, named FBE, was subsequently applied to an Amberlite FPX66Ô (Rohm and Haas, Philadelphia, USA) column (80 Â 10 cm I.D.) that had been equilibrated with water. After washing with water, the trapped material was eluted with 1 wt % NaOH. The eluted fraction was applied to an Amberlite IRC76Ô hydrogen-form (Rohm and Haas, Philadelphia, USA) column, the pass-through fraction being freeze-dried. Approximately 100 g of the freeze-dried sample, named FBEP, was obtained from 10 kg of PB. The composition of FBEP was as follows: carbohydrate, 41.8%; protein, 39.2%; dietary fiber, 8.8%; fat, 0.3%; ash, 3.7%; and water, 6.2%. We used a test drink containing 2 g per 30 ml for the daily intake of FBEP, and an FBEP-free placebo drink, which contained a small amount of caramel to produce the same color as the test drink, as the control. Both drinks contained equal amounts of honey, galacto-oligo saccharide, and lemon fruit juice as secondary components.
Trial design. A randomized, placebo-controlled, parallel-group, double-blind study was carried out. The primary end point was the change in serum uric acid level from pre-treatment to week 12 after the treatment. The secondary endpoints were the changes in urinary uric acid level and uric acid clearance from pre-treatment to the end of the treatment period. The test schedule is shown in Fig. 1 . We conducted a pre-test examination about 5 weeks prior to the trial. About 4 weeks later, we conducted an additional pre-test examination, after which we selected 111 subjects who qualified for the present study. The parameters monitored during the experiment are detailed in the test schedule which continued for a total of 21 weeks and comprised a 4-week recruitment period, 1-week pre-treatment period, 12-week treatment period, and 4-week post-experimental period. During the treatment period, the food consumption and changes in the physical conditions were recorded daily, a dietary survey for cataloging all food consumed was filled in for 3 d prior to the examination. Alcoholic beverages were not allowed in the 3 d prior to the examination, and no food or drinks, except water, were allowed 8 h prior to the examination. Urine was collected for 24 h prior to the examination by using U-mate P (Sumitomo Bakelite, Akita, Japan). The subjects were asked to visit the hospital without consuming the food to be used on the examination days during the treatment period. Uric acid clearance was calculated by using the classification for disease type in the Guidelines for the Management of Hyperuricemia and Gout.
3) The equation of Fujimoto et al. was used for calculating the body surface area in the formula for uric acid clearance rate.
12) However, we used urine collected for 24 h on the day before the examination as the samples in the present study, and did not follow the experimental procedure described in those guidelines.
Clinical laboratory parameters. i) Physical examination. A total of six measurements were taken for assessing the body weight (BW), blood pressure (BP) and pulse rate: once 5 weeks before treatment; once 1 week before treatment; then 4, 8, and 12 weeks during treatment; and lastly, once 4 weeks after treatment. Height (Ht) was measured only once, 5 weeks before the treatment, and was used to calculate the body-mass index (BMI).
ii) Blood and urine tests. Peripheral blood samples were monitored for the following indices: white blood cell (WBC), red blood cell (RBC), and platelet counts; hemoglobin (Hb) level; hematocrit (HMC) value; MCV, MCH, MCHC, AST, ALT, ALP, -GTP, LDH, total bilirubin (Tbil), fasting blood sugar (FBS), total protein (TP), and albumin (Alb) levels; A/G ratio; total cholesterol (Tcho), HDLcholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglyceride (TG) levels; blood urea nitrogen (BUN), creatinine (Cr), uric acid (UA); and electrolytes (Na, K, Cl, Ca, and P). Qualitative urine tests assessing the pH value, glucose, protein, and occult blood levels were performed by using test paper, while the uric acid level was quantitatively measured. Blood and urine were determined in a clinical laboratory (SRL, Tokyo, Japan).
Dietary survey. The intake of purine and alcoholic drinks during the study period was evaluated. The intake of purine is defined as the total purine content in the food and alcoholic drinks. Estimates of the purine content in different foods were obtained from the amounts of purine described in the Standard Tables of Food Composition in Japan (STJ) 13) and from the attached list of the Guidelines for the Management of Hyperuricemia and Gout. 3) We used values published on websites for each company producing alcoholic drinks for the purine content in these drinks. We utilized the purine content in foods described in STJ when this information was not available on the websites. The same measurement method for purine content data was applied. The purine intake over the 3 d prior to the examination (before treatment, 4, 8 and 12 weeks during treatment, and week 4 posttreatment) was calculated from the information in the dietary survey. We define the amount of alcoholic drinks as the alcohol intake (g) Unfilled circles, diagnostic interview; filled circles, physical examination; unfilled triangles, blood test; filled triangles, urine test; squares, diet survey.
calculated by the preference beverages described in STJ as the reference. The daily average of alcohol intake (g) was calculated from the data recorded in the diary.
Statistical analysis. The serum uric acid levels, urinary uric acid levels and uric acid clearance rates for the test and placebo groups were compared 12 weeks after the treatment with the pre-treatment values by an analysis of covariance, in which values obtained at the examination prior to the treatment are regarded as the covariance values. The other results were evaluated by using a paired t-test of the presence or absence of variation at weeks 4, 8, and 12 during treatment and at week 4 post-treatment in comparison with the pre-treatment values. Each value is expressed as the mean AE SD. All statistical tests were two-tailed, a p value of less than 0.05 being considered statistically significant.
Results
Background details of the subjects 468 applicants (410 men and 58 women) between the ages of 20 and 65 years consented to participate in the study, among whom 111 subjects passed the selection criteria and were not rejected according to the exclusion criteria. However, one subject dropped out for personal reasons. Thus, the total number of subjects who completed the prescribed study schedule was 110. Among the subjects, 5 were unreliable with respect to the examination results and 1 took medication that would affect the test results. Thus, 6 additional subjects were excluded during the study, leaving 104 valid subjects eligible for analysis. In respect of the subject who dropped out halfway, the period from the start of treatment up to the time of dropping out was used as the evaluation period, and all the values for the clinical and physical examinations up to week 4 were used as valid data. The results of the clinical and physical examinations in week 8 after treatment were evaluated for 109 subjects, excluding one who was found to be defective in week 8 after the intake. The background of the subjects is shown in Table 1 .
Serum uric acid
The time-course characteristics for serum uric acid are shown in Table 2 -2. The covariance analysis, in which the pre-treatment values were the covariates, showed a significant decrease in the test group 12 weeks after treatment (p < 0:05). The within-group comparison showed significantly lower values for the test group in weeks 4 and 12 during treatment than the pretreatment values. In contrast, the placebo group did not show any significant changes.
Urinary uric acid
The time-course characteristics for urinary uric acid are shown in Table 3 . The between-groups comparison showed no significant difference in week 12. However, the within-group comparison showed significantly higher values for the test group in week 12 of treatment than the pre-treatment values. In contrast, the placebo group did not exhibit any significant changes.
Urinary volume and pH
No significant changes were observed in either the between-groups or within-group analyses (data not shown).
Uric acid clearance
The time-course variations for uric acid clearance from the pre-treatment levels are shown in Fig. 2 . The covariance analysis shows a small elevation on week 12 of treatment in the test group when compared with the placebo group (p ¼ 0:054). Table 4 shows the physical examination findings. Both the test and placebo groups showed significantly lower diastolic blood pressure in weeks 8 and 12 of the treatment period than the pre-treatment values. Nevertheless, the changes at any determined time were within the normal range and are not regarded as clinically important decreases. The placebo group exhibited a significantly lower pulse rate in weeks 4 and 8 of the treatment and in week 4 of the post-experimental period than the pre-treatment values, although this decrease did not present any clinical problem. Such other parameters as the body weight, BMI and systolic blood pressure did not exhibit any significant changes.
Physical examination

Blood test
The time-course characteristics of the measurements are shown in Tables 2-1 and 2-2. Even though some significant variations were found in such multiple items as FBS during the treatment period and post-experimental period, the physician in charge of the study judged that these changes were not outside the normal range of variation and did not cause any clinical problems.
Urine test
The overall results are shown in Table 5 . Certain samples exhibited abnormal changes: in the test group, one item with two subjects (two subjects were positive for urine protein), and in the placebo group, two items with three subjects (two subjects were positive for urine protein, and one subject was positive for urine occult blood). Although the measured values were found to exceed the normal range in certain subjects, the values from the examinations taken in advance and the examination of the values of the other items for these WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin level; HMC, hematocrit; M, male; F, female. Each value is expressed as the mean AE SD. Significant differences are as follows: Ã p < 0:05, ÃÃ p < 0:01, compared with the pre-treatment condition using the paired Student's t-test.
subjects, were adjudged to pose no clinical problems by the physician in charge of the study.
Daily purine intake Table 6 shows the change in the daily average purine intake that was calculated from the dietary surveys over 3 d prior to the examination. No significant changes were apparent in either group as compared to the pretreatment levels.
Daily alcohol intake
Changes in the daily average alcohol intake calculated from the meal diaries were as follows: test group, 1:1 AE 9:2 g; placebo group, 3:2 AE 11:5 g in weeks 1-4; test group, 0:3 AE 9:7 g; placebo group, 1:7 AE 8:8 g in weeks 5-8; test group, À0:1 AE 8:7 g; placebo group, 0:5 AE 8:3 g in weeks 9-12; and test group, 1:0 AE 10:2 g; placebo group, 1:2 AE 8:8 g in the post-experimental period. These figures did not reveal any significant changes.
Discussion
FBEP, a primary component of the test food in the present study, had been found to significantly decrease the serum uric acid level in an open study using male Japanese subjects with a serum uric acid level in the range of 6.0-7.9 mg/dl. 11) Based on this result, we carried out a double-blind, parallel-group study of Japanese men and women with slightly elevated levels of serum uric acid to statistically confirm the effect of FBEP on decreasing the serum uric acid level (after having eliminated environmental factors and the placebo effects) and also to examine the safety of FBEP. We found that the FBEP-treated group exhibited a significantly lower serum uric acid level in week 12 of the treatment period than the placebo group. The withingroup comparison revealed that the test group exhibited significantly lower serum uric acid levels in weeks 4 and 12 of the treatment period than the pre-treatment levels, but that the levels in week 8 of the treatment period returned to the pre-treatment levels. Since the placebo group demonstrated little change in the serum uric acid level throughout the examination period, we examined the factors influencing the serum level of uric acid of the test group in week 8 of treatment. The purine and alcohol intake are closely related to serum uric acid, but no elevation of the intake of purine or alcohol by the test group was apparent in week 8 of treatment. The renal function is also closely related to serum uric acid, but no alteration in serum creatinine or blood urea nitrogen was apparent. In the case of the test group, the standard deviation of 0.73 in serum uric acid level in week 8 of treatment shows slight elevation, as compared to 0.64 in week 4 of treatment and to 0.62 in week 12 of treatment, indicating a wide variation of the measured values in week 8 of the treatment period.
On the other hand, an evaluation of the uric acid clearance that was carried out to examine a possible mechanism of action, and the test group showed a Unfilled circles, treatment group (n ¼ 54); filled diamonds, placebo group (n ¼ 50). Each value is expressed as the mean AE SD. # p < 0:10, compared with the placebo group using an analysis of covariance. slightly higher level in week 12 of treatment than the placebo group. Based on this result, it is suggested that the action of FBEP in reducing serum uric acid can possibly be attributed to the accelerated excretion of uric acid. Among the 54 subjects in the test group, the serum uric acid level in 10 subjects with a normal range of uric acid clearance was 6.94 mg/dl prior to treatment, changing to 6.88 mg/dl in week 4 of treatment, to 7.25 mg/dl in week 8 of treatment, and to 6.95 mg/dl in week 12 of treatment, although these changes were not significant throughout the period of intake. The influence of FBEP on the serum uric acid level in the subjects with an excessive production of uric acid is considered to have been low.
As characteristic components contained in FBEP, the secondary metabolites of Aspergillus species, which possess antioxidative activity, have been reported. 14) On the other hand, the intake of vitamin C, a water-soluble antioxidant, reduces the serum uric acid level. 15) Moreover, higher vitamin C intake has been independently associated with a lower risk of gout. 16) An increase in glomerular filtration and/or competition for renal reabsorption are considered as the mechanism by which vitamin C reduced serum uric acid. The mechanism by which FBEP reduced serum uric acid may have inhibited the renal reabsorption of uric acid by an ingredient like the vitamin C reabsorbed via anionexchange transport at proximal tubules.
The detailed mechanism for the molecular action of FBEP on the accelerated excretion of uric acid remains for future study. However, we have been examining the orotic acid-induced inhibitory effect of FBE on fatty liver in rats. 8) It has been reported that the level of human urate transporter 1 (URAT 1) was greatly reduced by a high level (1 mM) of orotic acid, 17) and that URAT 1 was responsible for transporting orotic acid across cell membranes, this transport being strongly blocked by benzbromarone which is a uric acid excretion-promoting drug. 18) In addition, human organic anion transporter (hOAT) 1 and hOAT 3 may be transporting some uric acid from the lumen of the blood vessels to renal tubular cells. 19, 20) It is also known that there is gender difference in the serum uric acid level, 21) for which uric acid clearance increased by estrogen has been reported to be a cause. 22) In other words, the uric acid transporter may be controlled by sex hormones. We now plan to carry out a further study identifying which constituent in the crude composition of FBEP was involved in mediating the serum uric acid-lowering effect, while paying attention to the organic anion transporter.
The safety of FBEP during 12 weeks of continuous intake, at 2 g/d, was confirmed by the findings that there was little change to cause clinical concern in the examined parameters (Tables 2, 4 , and 5), and that there were no symptomatic manifestations. FBEP The daily purine intake was estimated on the basis of the 3-d dietary surveys taken before the clinical examinations. Each value is expressed as the mean AE SD.
obtained from the combination of barley and the brewing microorganism, whose safety has been confirmed through the long years of dietary experience, is expected to be utilized as a side-effect-free, safe functional food material.
In conclusion, the results of the present study indicate that FBEP obtained by fermenting barley with fungus and yeast had the effect of significantly reducing the serum uric acid level in subjects with slightly elevated serum uric acid or mild hyperuricemia.
